Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CURELUNG

Financiado

Cerrado

Determining epi genetic therapeutic signatures for improving lung cancer progno...

Determining epi genetic therapeutic signatures for improving lung cancer prognosis Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated wit... ver más

30/06/2014

FUNDACIO INSTITUT...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-06-30 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

FUNDACIO INSTITUT D?INVESTIG...

0.00€ | Lider

INT

N.D. | Participante

THE UNIVERSITY OF LIVERPOOL

N.D. | Participante

MPG

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-128596OB-I00 ESTUDIO DEL MICROAMBIENTE TUMORAL PARA SUPERAR LA RESISTENCI... 169K€ Cerrado

SAF2014-54571-R DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS BASADAS EN EL PERF... 290K€ Cerrado

SAF2017-85352-R REPROGRAMACION METABOLICA Y EPIGENETICA MEDIADA POR NNMT DUR... 109K€ Cerrado

BES-2015-072204 DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS BASADAS EN EL PERF... 93K€ Cerrado

SAF2013-49056-R ANALISIS GENOMICO-FUNCIONAL DE LA RESISTENCIA A LAS TERAPIAS... 133K€ Cerrado

PID2021-122741OB-I00 IDENTIFICACION DE NUEVAS OPORTUNIDADES TERAPEUTICAS CAUSADAS... 230K€ Cerrado

Líder del proyecto

FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understanding of the epigenetic and genetic profile of LC, such knowledge has contributed little to improving therapeutics. This scenario, however, is likely to change soon because several specific cancer therapies, targeting molecules that are altered in cancer, are being developed or are already undergoing clinical trials. Thinking ahead, our proposal focuses, on the one hand, on validating novel and specific therapeutic strategies, with particular emphasis on discovering (epi)genetic alterations that could act as novel targets for therapies, and, on the other, on defining the (epi)genetic markers that could determine the efficacy response or resistance to targeted therapies as well as the acquired resistance of the tumours to therapy. To reach our goals, we have designed an integrative and interdisciplinary approach involving leading European clinical scientists of international renown with prominent preclinical and basic research groups using high throughput and state-of-the art platforms for genomics and gene expression analysis. To date, no such comprehensive information exists. The results will be of great value for the stratification of lung tumours according to their genetic background for tailored treatments. The development of an (epi)genetic-based therapeutic prediction model will hopefully set the basis for future tailored treatment of LC as well as of other epithelial cancers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores